Literature DB >> 19639394

Role of convective flow in carmustine delivery to a brain tumor.

Davis Yohanes Arifin1, Kam Yiu Timothy Lee, Chi-Hwa Wang, Kenneth A Smith.   

Abstract

PURPOSE: This paper presents a three-dimensional patient-specific simulation of carmustine delivery to brain tumor. The simulation investigates several crucial factors, particularly the role of convective flow, affecting drug delivery efficacy.
METHODS: The simulation utilizes a complete three-dimensional tissue geometry constructed from magnetic resonance images (MRI) of a brain tumor patient in whom commercially available Gliadel wafers were implanted for sustained delivery of carmustine following excision of the tumor. This method permits an estimation of the convective flow field (in the irregularly shaped anatomical region) which can be used for prediction of drug penetration into the domain of interest, i.e. remnant tumor. A finite volume method is utilized to perform all simulations.
RESULTS: Drug exposure exceeds its threshold therapeutic concentration (approximately 15 microM) but for only a limited time (i.e. less than a week) and only in the immediately adjacent tissue (i.e. less than 2 mm). A quasi-steady transport process is established within 1 day following treatment, in which the drug is eliminated rapidly by transcapillary exchange, while its penetration into the tumor is mainly by diffusion. Convection appears to be crucial in influencing the drug distribution in the tumor: the remnant tumor near the ventricle is, by one to two orders of magnitude, less exposed to the drug than is the distal remnant tumor.
CONCLUSIONS: Carmustine penetration from Gliadel wafers implanted in brain is limited by rapid elimination via transcapillary exchange. Therefore, it could be useful to consider other therapeutic agents such as paclitaxel. In addition, local convective flow within the cavity appears to be a crucial factor in distributing the drug so that the tumor domain near the ventricle is prone to minimal drug exposure. Thus, complete removal of the tumor from this region is of particular concern.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19639394     DOI: 10.1007/s11095-009-9945-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  35 in total

1.  Interstitial pressure, volume, and flow during infusion into brain tissue.

Authors:  P J Basser
Journal:  Microvasc Res       Date:  1992-09       Impact factor: 3.514

Review 2.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

3.  Microvascular permeability of normal and neoplastic tissues.

Authors:  L E Gerlowski; R K Jain
Journal:  Microvasc Res       Date:  1986-05       Impact factor: 3.514

4.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

Review 5.  Barriers to carrier mediated drug and gene delivery to brain tumors.

Authors:  Grace H Huynh; Dennis F Deen; Francis C Szoka
Journal:  J Control Release       Date:  2005-11-28       Impact factor: 9.776

6.  Computer simulation of the delivery of etanidazole to brain tumor from PLGA wafers: comparison between linear and double burst release systems.

Authors:  Wilson Hor Keong Tan; Fangjing Wang; Timothy Lee; Chi-Hwa Wang
Journal:  Biotechnol Bioeng       Date:  2003-05-05       Impact factor: 4.530

Review 7.  High interstitial fluid pressure - an obstacle in cancer therapy.

Authors:  Carl-Henrik Heldin; Kristofer Rubin; Kristian Pietras; Arne Ostman
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

8.  Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma.

Authors:  Sudhir H Ranganath; Chi-Hwa Wang
Journal:  Biomaterials       Date:  2008-04-18       Impact factor: 12.479

9.  Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.

Authors:  Alf Giese; Thomas Kucinski; Ulrich Knopp; Roland Goldbrunner; Wolfgang Hamel; H M Mehdorn; Jörg C Tonn; Dana Hilt; Manfred Westphal
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

Review 10.  Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection.

Authors:  L T Baxter; R K Jain
Journal:  Microvasc Res       Date:  1989-01       Impact factor: 3.514

View more
  15 in total

1.  Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy.

Authors:  Wenbo Zhan; Davis Yohanes Arifin; Timothy Ky Lee; Chi-Hwa Wang
Journal:  Pharm Res       Date:  2017-02-02       Impact factor: 4.200

2.  Convection-Enhanced Delivery of Antiangiogenic Drugs and Liposomal Cytotoxic Drugs to Heterogeneous Brain Tumor for Combination Therapy.

Authors:  Ajay Bhandari; Kartikey Jaiswal; Anup Singh; Wenbo Zhan
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

3.  Translation of the ecological trap concept to glioma therapy: the cancer cell trap concept.

Authors:  Boudewijn van der Sanden; Florence Appaix; François Berger; Laurent Selek; Jean-Paul Issartel; Didier Wion
Journal:  Future Oncol       Date:  2013-06       Impact factor: 3.404

Review 4.  Prediction of drug disposition on the basis of its chemical structure.

Authors:  David Stepensky
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

5.  Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.

Authors:  Elizabeth G Graham-Gurysh; Ananya B Murthy; Kathryn M Moore; Shawn D Hingtgen; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2020-04-23       Impact factor: 9.776

6.  Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection.

Authors:  Elizabeth Graham-Gurysh; Kathryn M Moore; Andrew B Satterlee; Kevin T Sheets; Feng-Chang Lin; Eric M Bachelder; C Ryan Miller; Shawn D Hingtgen; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-02-02       Impact factor: 4.939

7.  Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.

Authors:  Lawrence Kleinberg
Journal:  Core Evid       Date:  2012-10-26

Review 8.  Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues.

Authors:  Munju Kim; Robert J Gillies; Katarzyna A Rejniak
Journal:  Front Oncol       Date:  2013-11-18       Impact factor: 6.244

9.  Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.

Authors:  Steven Brem; Christina A Meyers; Gary Palmer; Margaret Booth-Jones; Surbhi Jain; Matthew G Ewend
Journal:  Cancer       Date:  2013-08-23       Impact factor: 6.860

10.  Mathematical Based Calculation of Drug Penetration Depth in Solid Tumors.

Authors:  Hamidreza Namazi; Vladimir V Kulish; Albert Wong; Sina Nazeri
Journal:  Biomed Res Int       Date:  2016-06-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.